Follow-up examinations take place at 3, 6, 9, 12, 18 and 24 months after the inclusion of the patient in the trial. On each visit the medical history shall include information on date of recurrent stroke, date of transient ischaemic attacks (TIA), date of gastro-intestinal bleeding, other bleeding episodes, and date of MI, falls, and fractures, and date of any serious adverse events.